Phase II study of gemcitabine/S-1 combination therapy in patients with non-resectable advanced biliary tract cancer
Phase 2
- Conditions
- non-resectable biliary tract cancer or recurrent biliary tract cancer post surgical treatment
- Registration Number
- JPRN-UMIN000000792
- Lead Sponsor
- Kyoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with interstitial pneumonia or pulmonary fibrosis 2. Patients with uncontrollable diabetes mellitus, liver disease, angina pectoris or a new onset of myocardial infarction within 3 months 3. Patients with severe active infection 4. Patients who are pregnant or lactating, or have an intention to get pregnant 5. Patients with a history of severe drug allery 6. Patients with other serious comorbid disease 7. Patinets with serious mental disease 8. Patients who are judged inappropriate for the entry into the study by the investigater
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method